DietarySupplement.com - FDA Approves CAR T Therapy for Large B-Cell Lymphoma Developed at University of Pennsylvania http://www.dietarysupplement.com/review/story.php?title=fda-approves-car-t-therapy-for-large-b-cell-lymphoma-developed-at-university-of-pennsylvania The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, this time for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy. Today's approval includes treatment of diffuse large B-cell lymphoma (DLBCL) - the most common form of non-Hodgkin's lymphoma - as well as high grade Read MoreB-cell lymphoma and DLBCL arising from follicular lymphoma. Mon, 18 Jun 2018 15:55:42 UTC en